Nuvectis Pharma Inc (NVCT)

May 16, 2025

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewswire

May 16, 2025

May 12, 2025

Nuvectis pharma investor Charles Mosseri Marlio buys $247k in stock By Investing.com - Investing.com India

May 12, 2025

May 12, 2025

Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect? - MSN

May 12, 2025

May 10, 2025

Q2 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright - Defense World

May 10, 2025

May 10, 2025

Roth Capital Forecasts Stronger Earnings for Nuvectis Pharma - Defense World

May 10, 2025

May 09, 2025

Nuvectis Pharma Launches New $60M Stock Offering Program - TipRanks

May 09, 2025

May 09, 2025

Nuvectis Pharma launches public stock offering - MSN

May 09, 2025

May 08, 2025

(NVCT) Investment Report - news.stocktradersdaily.com

May 08, 2025

May 08, 2025

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

May 08, 2025

May 07, 2025

Nuvectis Pharma Reports Q1 2025 Progress and Financials - TipRanks

May 07, 2025

May 06, 2025

Nuvectis Pharma reports Q1 EPS (27c) vs (25c) last year - TipRanks

May 06, 2025

May 06, 2025

Nuvectis (NVCT) Advances Clinical Programs with Promising Updates | NVCT Stock News - GuruFocus

May 06, 2025

May 06, 2025

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

May 06, 2025

May 03, 2025

Nuvectis Pharma’s (NVCT) “Buy” Rating Reiterated at HC Wainwright - Defense World

May 03, 2025

May 01, 2025

Buy Rating for Nuvectis Pharma: Promising Phase 1 Trial Results of NXP900 Highlight Potential in Combination Therapies - TipRanks

May 01, 2025

Apr 30, 2025

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 - Insider Monkey

Apr 30, 2025

Apr 30, 2025

Nuvectis Pharma (NVCT) Price Target Raised Due to Promising Scientific Insights | NVCT Stock News - GuruFocus

Apr 30, 2025

Apr 29, 2025

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting - The Manila Times

Apr 29, 2025

Apr 29, 2025

Nuvectis Pharma, Inc. Announces Positive Phase 1a Data for NXP900 Demonstrating Robust Pharmacodynamic Responses and Acceptable Safety Profile - Nasdaq

Apr 29, 2025

Apr 29, 2025

Breakthrough: Nuvectis NXP900 Cancer Drug Achieves 90% Target Inhibition in Phase 1 Trial - Stock Titan

Apr 29, 2025

Apr 25, 2025

Nuvectis Pharma (NASDAQ:NVCT) Trading 5.3% Higher – Here’s What Happened - Defense World

Apr 25, 2025

Apr 23, 2025

(NVCT) Trading Signals - news.stocktradersdaily.com

Apr 23, 2025

Apr 18, 2025

Is Nuvectis Pharma Inc (NASDAQ: NVCT) A Good Pick For New Investors Now? - Stocksregister

Apr 18, 2025

Apr 16, 2025

Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN

Apr 16, 2025

Apr 15, 2025

Nuvectis pharma investor acquires $1.2 million in stock - MSN

Apr 15, 2025

Apr 15, 2025

Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$36m last week; individual investors who hold 48% profited and so did insiders - simplywall.st

Apr 15, 2025

Apr 14, 2025

SCHD ETF News, 4/14/2025 - The Globe and Mail

Apr 14, 2025

Apr 06, 2025

When the Price of (NVCT) Talks, People Listen - news.stocktradersdaily.com

Apr 06, 2025

Apr 05, 2025

Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World

Apr 05, 2025

Apr 04, 2025

Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT) - Defense World

Apr 04, 2025

Apr 02, 2025

Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq

Apr 02, 2025

Apr 02, 2025

Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target - MarketScreener

Apr 02, 2025

Mar 29, 2025

Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference - MarketScreener

Mar 29, 2025

Mar 27, 2025

(NVCT) Investment Analysis - news.stocktradersdaily.com

Mar 27, 2025

Mar 27, 2025

CEO ClipsOrvana Minerals: Expanding Gold, Silver & Copper Production Across Key Global Regions - The Globe and Mail

Mar 27, 2025

Mar 26, 2025

Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire

Mar 26, 2025

Mar 26, 2025

New Cancer Treatment Breakthrough: NXP900 Data Showcase at Major AACR Conference - Stock Titan

Mar 26, 2025

Mar 21, 2025

Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Large Decline in Short Interest - Defense World

Mar 21, 2025

Mar 18, 2025

Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Laidlaw - Defense World

Mar 18, 2025

Mar 17, 2025

Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq

Mar 17, 2025

Mar 17, 2025

Laidlaw starts Nuvectis Pharma stock with Buy, $19 target By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

Nuvectis Pharma initiated with a Buy at Laidlaw - TipRanks

Mar 17, 2025

Mar 17, 2025

Laidlaw starts Nuvectis Pharma stock with Buy, $19 target - Investing.com

Mar 17, 2025

Mar 16, 2025

(NVCT) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 16, 2025

Mar 14, 2025

Nuvectis Pharma to Participate in the 37th Annual Roth Conference - GlobeNewswire

Mar 14, 2025

Mar 14, 2025

Nuvectis Pharma CEO Fireside Chat: Key Oncology Pipeline Updates Coming at Roth Conference - StockTitan

Mar 14, 2025

Mar 10, 2025

Oppenheimer & Co. Inc. Takes Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World

Mar 10, 2025

Mar 06, 2025

(NVCT) Proactive Strategies - Stock Traders Daily

Mar 06, 2025

Mar 04, 2025

Nuvectis announces new publication of research study on NXP900, osimertinib - TipRanks

Mar 04, 2025

Mar 04, 2025

Nuvectis reports promising cancer treatment results - Investing.com

Mar 04, 2025